Increased plasma DPP4 activity predicts new-onset hypertension in Chinese over a 4-year period: Possible associations with inflammation and oxidative stress

Journal of Human Hypertension

Volumn 29, Issue 7, 2015, Pages 424-429

  Zheng, T ^a,b   Chen, T ^a   Liu, Y ^c   Gao, Y ^a   Tian, H ^a  

^a SICHUAN UNIVERSITY   (China)

^b GUILIN MEDICAL UNIVERSITY   (China)

^c Diabetic Centre of Control and Prevention People's Liberation Army 520 Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ALCOHOL; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; PROSTAGLANDIN F2 ALPHA; SOMATOMEDIN B RECEPTOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, HUMAN; SOMATOMEDIN B;

ADULT; AGED; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHINESE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NEW ONSET HYPERTENSION; OXIDATIVE STRESS; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO; BLOOD; ENZYMOLOGY; PROPORTIONAL HAZARDS MODEL;

ADULT; C-REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN-LIKE GROWTH FACTOR II; INTERLEUKIN-6; MALE; OXIDATIVE STRESS; PROPORTIONAL HAZARDS MODELS;

EID: 84930868649     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2014.111     Document Type: Article

References (24)

1. Gao Y, Chen G, Tian H, Lin L, Lu J, Weng J et al. Prevalence of hypertension in China: a cross-sectional study. PLoS ONE 2013; 8: e65938.
2. Ryan MJ. An update on immune system activation in the pathogenesis of hypertension. Hypertension 2013; 62: 226-230.
3. Virdis A, Dell'Agnello U, Taddei S. Impact of inflammation on vascular disease in hypertension. Maturitas 2014; 78: 179-183.
4. Leibowitz A, Schiffrin EL. Immune mechanisms in hypertension. Curr Hypertens Rep 2011; 13: 465-472.
5. Rodrigo R, Gonzalez J, Paoletto F. The role of oxidative stress in the pathophysiology of hypertension. Hypertens Res 2011; 34: 431-440.
6. Zalba G, San Jose G, Moreno MU, Fortuno MA, Fortuno A, Beaumont FJ et al. Oxidative stress in arterial hypertension: role of nad(p)h oxidase. Hypertension 2001; 38: 1395-1399.
7. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (cd26): knowing the function before inhibiting the enzyme. Curr Med Chem 2009; 16: 2943-2951.
8. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60: 1917-1925.
9. Itou M, Kawaguchi T, Taniguchi E, Sata M. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol 2013; 19: 2298-2306.
10. Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (dpp4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013; 226: 305-314.
11. Cordero OJ, Salgado FJ, Vinuela JE, Nogueira M. Interleukin-12 enhances cd26 expression and dipeptidyl peptidase iv function on human activated lymphocytes. Immunobiology 1997; 197: 522-533.
12. Ikushima H, Munakata Y, Iwata S, Ohnuma K, Kobayashi S, Dang NH et al. Soluble cd26/dipeptidyl peptidase iv enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor ii receptor. Cell Immunol 2002; 215: 106-110.
13. Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor ii receptor. Cardiovasc Diabetol 2013; 12: 125.
14. Mason RP, Jacob RF, Kubant R, Ciszewski A, Corbalan JJ, Malinski T. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sicam-1 levels in hypertensive rats. J Cardiovasc Pharmacol 2012; 60: 467-473.
15. Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 2011; 223: 133-135.
16. Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008; 48: 592-598.
17. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J et al. Prevalence of diabetes among men and women in china. N Engl J Med 2010; 362: 1090-1101.
18. Alderman M, Arakawa K, Beilin L, Chalmers J, Erdine S, Fujishima M et al. 1999 world health organization-international society of hypertension guidelines for the management of hypertension. Guidelines sub-committee. Blood Press Suppl 1999; 1: 9-43.
19. Rose GA, Blackburn H. Cardiovascular survey methods. Monogr Ser World Health Organ 1968; 56: 1-188.
20. Yang F, Zheng T, Gao Y, Baskota A, Chen T, Ran X et al. Increased plasma dpp4 activity is an independent predictor of the onset of metabolic syndrome in chinese over 4 years: result from the china national diabetes and metabolic disorders study. PLoS ONE 2014; 9: e92222.
21. Nelson KM, Boyko EJ, Koepsell T. All-cause mortality risk among a national sample of individuals with diabetes. Diabetes Care 2010; 33: 2360-2364.
22. Kirino Y, Sei M, Kawazoe K, Minakuchi K, Sato Y. Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people. Endocr J 2012; 59: 949-953.
23. Jeyaratnaganthan N, Hojlund K, Kroustrup JP, Larsen JF, Bjerre M et al. Circulating levels of insulin-like growth factor-ii/mannose-6-phosphate receptor in obesity and type 2 diabetes. Growth Horm IGF Res 2010; 20: 185-191.
24. Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes Obes Metab 2009; 11: 611-622.